Top

Cancer Chemotherapy and Pharmacology

Published in:

01-01-2008 | Review

Third-line therapy for metastatic colorectal cancer

Authors: M. G. Gundgaard, J. B. Soerensen, E. Ehrnrooth

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2008

Abstract

Background

The past years’ therapy for colorectal cancer has evolved rapidly with the introduction of novel cytotoxic agents such as irinotecan, capecitabine and oxaliplatin. Further advances have been achieved with the integration of targeted agents such as bevacizumab, cetuximab and recently, panitumumab. As a result, third-line treatment is now a necessary step in the optimal treatment of patients with metastatic colorectal cancer (MCRC).

Materials and methods

We conducted a literature review of English language publications on third-line therapy for MCRC from January 2000 to April 2007. Data on median overall survival (mOS), median time to progression (mTTP) and response rate were recorded.

Results

We found 27 articles and 22 abstracts to fulfil the criteria. Patients who received regimens containing oxaliplatin and infusional 5-fluorouracil (5-FU) demonstrated mTTP up to 7 months and a mOS of 16 months. With irinotecan and 5-FU, mOS around 8 months were reported and with cetuximab combined with irinotecan, the highest mOS was 9.8 months.

Conclusion

Third-line therapy in advanced colorectal cancer may improve mOS for patients with MCRC. Therefore, randomized studies should be conducted in the future.

Cunningham D, Findlay M (1993) The chemotherapy of colon cancer can no longer be ignored. Eur J Cancer 29A(15):2077–2079PubMedCrossRef

de Gramont A, Bosset J-F, Milan C, Rougier P, Bouché O, Etienne P-L, Marvan F, Louvet C, Guillot T, François E, Bedenne L (1997) Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 15(2):808–815PubMed

Cunningham D, Pyrhönen S, James RD, Punt CJA, Hickish TF, Heikkila R, Johannesen TB, Starkhammer H, Topham CA, Awad L, Jacques C, Herait P (1998) Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352(9138):1413–1418PubMedCrossRef

Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, Wils J, Awad L, Herait P, Jacques C (1998) Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352(9138):1407–1412PubMedCrossRef

de Gramont A, Vignoud J, Tournigand C, Louvet C, André T, Varette C, Raymond E, Moreau S, Le Bail N, Krulik M (1997) Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 33(2):214–219PubMedCrossRef

Rothenberg ML, Oza AM, Bigelowe RH, Berlin JD, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, Le Bail N, Haller DG (2003) Superiority of oxaliplatin and fluorouracil–leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil–leucovorin: interim results of a phase III trial. J Clin Oncol 21(11):2059–2069PubMedCrossRef

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335–2342PubMedCrossRef

Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351(4):337–345PubMedCrossRef

US Food and Drug Administration. www.FDA.gov

10.

Rowland KM, Pitot HC, Sargent DJ, Philip PA, Mitchell EP, Mailliard JA, Goldberg RM, Alberts SR (2005) Results of 3rd line therapy on N9841: a randomized phase III trial of oxaliplatin/5-fluorouracil (5FU)/leucovorin (FOLFOX4) versus irinotecan (CPT-11) in patients (pts) with advanced colorectal cancer (CRC) previously treated with prior 5FU chemotherapy. Proc ASCO, annual meeting, abstract no 3519

11.

Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25(13):1658–1664PubMedCrossRef

12.

Kemeny N, Garay CA, Gurtler J, Hochster H, Kennedy P, Benson A, Brandt DS, Polikoff J, Wertheim M, Shumaker G, Hallman D, Burger B, Gupta S (2004) Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer. J Clin Oncol 22(23):4753–4761PubMedCrossRef

13.

Salek T (2005) Oxaliplatin, bolus 5-fluorouracil (5-FU) and leucovorin (LV/b-FOL) in heavily pretreated patients with metastatic colorectal cancer. National Cancer Institute Slovakia, the first “b-FOL” experience. ESMO, abstract no 70

14.

Chau I, Webb A, Cunningham D, Hill M, Waters JS, Norman A, Massey A (2001) Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer. Br J Cancer 85(9):1258–1264PubMedCrossRef

15.

Abón G, Muňoz A, Rubio I, Manel MJ, Ferreiro J, Fernández R, Fuente N, López AG, Barceló R, López VG (2000) Third line oxaliplatin with leucovorin (LV) and continuous infusion 5-fluorouracil (5FU) in metastatic colorectal cancer. ESMO, abstract no 211P

16.

Luppi G, Zanelli F, Di Stasi A, Bertolini F, Pifferi M (2002) Folfox 2 regimen in heavily pretreated patients with advanced colorectal cancer. Tumori 88(4):270–272PubMed

17.

Martoni A, Mini E, Pinto C, Nobili S, Gentile AL, Dentico P, Angelelli B, Scicolone S, Piana E, Mazzei T (2001) Oxaliplatin and protracted continuous 5-fluorouracil infusion in patients with pretreated advanced colorectal carcinoma. Ann Oncol 12(4):519–524PubMedCrossRef

18.

Mosconi S, Cascinu S, Zaniboni A, Catalano V, Giordani P, Beretta GD, Martignoni G, Pancera G, Baldelli AM, Poletti P, Curti C, Labianca R (2000) The value of oxaliplatin in combination with continuous infusion ± bolus 5-fluorouracil and levo-folinic acid in metastatic colorectal cancer progressing after 5FU-based chemotherapy: a GISCAD (Italian Group for the study of digestive tract) cancer phase II trial. Tumori 86(6):465–469PubMed

19.

Kallen K-J, Hofmann MAK, Timm A, Gödderz W, Galle PR, Heike M (2000) Weekly oxaliplatin, high-dose infusional 5-fluorouracil and folinic acid as palliative third-line therapy of advanced colorectal carcinoma. Z Gastroenterol 38:153–157PubMedCrossRef

20.

Giacchetti S, Zidani R, Chollet P, Dogliotti L, Kunstlinger F, Le Rol A, Garufi C, Brienza S, Focan C, Bertheault-Cvitkovic F, Misset J, Lévi F (2000) Chronotherapy of metastatic colorectal cancer (MCC) with 5-fluorouracil (5-FU)-leucovorin (LV)-oxaliplatin (L-OHP) as second to seventh line treatment. Proc ASCO, annual meeting, abstract no 1255

21.

Croles N, Smorenburg CH, van Groeningen CJ, Giaccone G, Boven E (2004) FOLFOX3 in heavily pretreated patients with metastatic colorectal cancer. Neth J Med 62(7/8):242–245PubMed

22.

Moehler M, Hoffmann T, Hildner K, Siebler J, Galle PR, Heike M (2002) Weekly oxaliplatin, high-dose folinic acid and 24h-5-fluorouracil (FUFOX) as salvage therapy in metastatic colorectal cancer patients pretreated with irinotecan and folinic acid/5-fluorouracil regimens. Z Gastroenterol 40:957–964PubMedCrossRef

23.

Bensmaïne MA, Marty M, de Gramont A, Brienza S, Lévi F, Ducreux M, François E, Gamelin E, Bleiberg H, Cvitkovic E (2001) Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) ± folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients. Br J Cancer 85(4):509–517PubMedCrossRef

24.

Gervais H, Artru P, Louvet C, Tournigand C, Maindrault F, Garcia M-L, de Gramont A (2002) Reintroduction of irinotecan in pretreated patients with metastatic colorectal cancer. Proc ASCO, annual meeting, abstract no 688

25.

Kim HJ, Kwon HC, Kim SH, Kim JS (2003) Irinotecan with biweekly, low-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for oxaliplatin pretreated metastatic colorectal cancer. Proc ASCO, annual meeting, abstract no 1196

26.

Maindrault F, Louvet C, André T, Gilles V, Artru P, Tournigand C, Garcia M, Gervais H, Carola E, Krulik M, de Gramont A (2001) Time to disease control (TDC) to evaluate the impact on survival of three chemotherapy lines in metastatic colorectal cancer (MRC) based on 5-fluorouracil, oxaliplatin and irinotecan (GERCOR) Proc ASCO, annual meeting, abstract no 581

27.

Stickel F, Jüngert B, Brueckl V, Schirner I, Brueckl WM, Männlein G, Hegewald J, Mühldorfer S, Bittorf B, Hohenberger W, Hahn EG, Wein A (2003) Weekly high-dose 5-fluorouracil as 24-h infusion and folinic acid (AIO) plus irinotecan as second- and third-line treatment in patients with colorectal cancer pre-treated with AIO plus oxaliplatin. Anticancer Drugs 14(9):745–749PubMedCrossRef

28.

Ardavanis AS, Ioannidis GN, Orphanos GS, Rigatos GA (2006) Salvage treatment with single-agent capecitabine in patients with heavily pretreated advanced colorectal cancer. Anticancer Res 26(2B):1669–1672PubMed

29.

Gubanski M, Naucler G, Almerud A, Lidestahl A, Lind P ARM (2005) Capecitabine as third line therapy in patients with advanced colorectal cancer. Acta Oncol 44(3):236–239PubMedCrossRef

30.

Lim DH, Park YS, Park BB, Ji SH, Lee J, Park KW, Kang JH, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Im YH, Kang WK, Park K (2005) Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study. Cancer Chemother Pharmacol 56(1):10–14PubMedCrossRef

31.

Harba A, Jordan K, Kegel I, Behrens R, Grothey A, Schmoll HJ (2003) Capecitabine/mitomycin C as salvage therapy in oxaliplatin and CPT11 refractory advanced colorectal carcinoma (ACRC). Proc ASCO, annual meeting, abstract no 1335

32.

Chong G, Dickson JLB, Cunningham D, Norman RA, Rao S, Hill ME, Price TJ, Oates J, Tebbutt N (2005) Capecitabine and mitomycin C as a 3rd line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. Br J Cancer 93(5):510–514PubMedCrossRef

33.

Jeung HC, Rha SY, Cho BC, Yoo NC, Roh JK, Roh WJ, Chung HC, Ahn JB (2006) A phase II trial of oral S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan-and oxaliplatin containing regimens. Br J Cancer 95(12):1637–1641PubMedCrossRef

34.

Tsavaris N, Kosmas C, Vadiaka M, Kontos A, Fotia M, Angelopoulou A, Vrizidis N, Soulla M, Sougioultzis S, Koufos Ch (2002) Raltitrexed (Tomudex) administration in patients failing multiple prior chemotherapy regimens in advanced colorectal cancer: a pilot study. Invest New Drugs 20:133–136PubMedCrossRef

35.

Garcia M, Gilles V, Louvet C, Defrance R, Tournigand C, Artru P, Maindrault-Goebel F, de Gramont A, Krulik M (2000) Bi-weekly irinotecan (CPT-11) combined with raltitrexed (“Tomudex”) treatment in heavily pre-treated patients with advanced colorectal cancer: a feasibility study. Proc ASCO, annual meeting, abstract no 987

36.

Rosati G, Rossi A, Germano D, Reggiardo G, Manzione L (2003) Raltitrexed and mitomycin-C as third-line chemotherapy for colorectal cancer after combination regimens including 5-fluorouracil, irinotecan and oxaliplatin: a phase II study. Anticancer Res 23(3C):2981–2985PubMed

37.

Lonardi S, Paris MK, Stefani M, Caroti C, D’Amico M, Jirillo A, Pronzato P, Gallo L, Monfardini S, Aschele C (2004) Gemcitabine (GEM) as salvage therapy in patients (pts) with advanced colorectal cancer (CRC) refractory to 5-fluorouracil (FU), irinotecan (IRI) and oxaliplatin (OXA). Proc ASCO, annual meeting, abstract no 3577

38.

Pachon V, Garcia-Alfonso P, Iglesias L, Siso I, Abad G, Khosravi P, Diaz V, Perez-Manga G (2005) Gemcitabine plus continuous infusion of 5-FU for heavily pretreated advanced colorectal cancer patients. Phase I/II study. Proc ASCO, annual meeting, abstract no 3735

39.

Hartmann JT, Oechsle K, Jäger E, Reis HE, Haag C, Niederle N, Wilke H-J, Pflüger K-H, Batran SAl, Büchele T, Hofheinz RD, Kanz L, Bokemeyer C (2004) Prospective multicenter phase II study of irinotecan as third line therapy in metastatic colorectal cancer and progression after bolus and infusional 5-fluorouracil. Anticancer Drugs 15(5):473–477PubMedCrossRef

40.

Benavides M, García-Alfonso P, Cobo M, Muňoz-Martín A, Gil-Calle S, Carabantes F, Villar E, Graupera J, Balcells M, Pérez-Manga G (2004) Weekly irinotecan (CPT-11) in 5-FU heavily pretreated and poor-performance-status patients with advanced colorectal cancer. Med Oncol 21(3):255–262PubMedCrossRef

41.

Gholam D, Giacchetti S, Brezault Bonnet C, Bouchahda M, Hauteville D, Adam R, Decot B, Ghémard O, Kustlinger F, Jasmin C, Levi F (2006) Chronomodulated irinotecan, oxaliplatin, and leucovorin-modulated 5-fluorouracil as ambulatory salvage therapy in patients with irinotecan-and oxaliplatin-resistant metastatic colorectal cancer. Oncologist 11(10):1072–1080PubMedCrossRef

42.

Polus M, Peeters M, Baert F, Vergauwe P, Kalantari H, Hendrickx K, Collignon J, van Maele P, Vandeputte L, van Laethem JL (2004) CPT-11 and mitomycin-C in heavily pre-treated patients with metastatic colorectal cancer: a Belgian multicentre phase II study. Proc ASCO, annual meeting, abstract no 3716

43.

Schulz J, Keller A, Canfield V, Parker G, Douglass E (2004) ZD9331 as second- or third-line therapy in patients with advanced colorectal cancer: a phase II multicenter trial. Am J Clin Oncol 27(4):337–342PubMedCrossRef

44.

Gollasch H, Gebauer B, Sturm I, Thuss-Patience P, Pink D, Stroszczynski C, Kretzschmar A (2004) Hepatic artery infusion (HAI) of oxaliplatin (Ox) as third and fourth-line therapy for patients with hepatic metastases (M) from colorectal cancer (CRC) pretreated with systemic Ox. Proc ASCO, annual meeting, abstract no 3695

45.

Mirtsching B, Headlee C, Beasley S, Teel C, Jackson D (2004) Cetuximab single-agent activity in refractory metastatic colorectal cancer: single-center experience. Proc ASCO, annual meeting, abstract no 3703

46.

Lenz HJ, Van Cutsem E, Khambata-Ford S, Mayer RJ, Gold P, Stella P, Mirtsching B, Cohn AL, Pippas AW, Azarnia N, Tsuchihashi Z, Mauro DJ, Rowinsky EK (2006) Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 24(30):4914–4921PubMedCrossRef

47.

Mirtsching BC, Cichon J, Beasly S, Teel C, Jackson D, Headlee C (2005) Cetuximab in refractory metastatic colorectal cancer: analysis of efficacy and response by patient and disease variables. Proc ASCO, gastrointestinal symposium, abstract no 205

48.

Vincenzi B, Santini D, Rabitti C, Coppola R, Beomonte Zobel B, Trodella L, Tonini G (2006) Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial. Br J Cancer 94(6):792–797PubMedCrossRef

49.

Grande C, Mel JR, Salgado M, Reboredo M, Candamio S, Fernandez I, Quintero G, Huidobro G, Firvida JL, Valladares M (2006) Multicenter phase II study of cetuximab and irinotecan as third line chemotherapy in patients (pts) with metastatic colorectal cancer (MCRC) previously treated with both irinotecan and oxaliplatin regimens. Proc ASCO, annual meeting, abstract no 13551

50.

Grothe W, Arnold D, Peinert S, Voigt W, Mantovani Loeffler L, Siewczynski R, Steps G, Boehme J, Graeven U, Schmoll H (2005) Cetuximab with oxaliplatin and capecitabine (CAPOX) in patients with metastatic colorectal cancer (mCRC) refractory to standard chemotherapy. Proc ASCO, annual meeting, abstract no 3669

51.

Chen HX, Mooney M, Boron M, Vena D, Mosby K, Grochow L, Jaffe C, Rubinstein L, Zwiebel J, Kaplan RS (2006) Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI treatment referral center trial TRC-0301. J Clin Oncol 24(21):3354–3360PubMedCrossRef

52.

Emmanouilides C, Pegram M, Robinson R, Hecht R, Kabbinavar F, Isacoff W (2004) Anti-VEGF antibody bevacizumab (Avastin) with 5FU/LV as third line treatment for colorectal cancer. Tech Coloproctol 8(Suppl 1):50–52CrossRef

53.

Peinert S, Arnold D, Grothe W, Lesske J, Siewczynski R, Schädlich B, Kegel T, Behrmann C, Schmoll H-J (2005) Salvage therapy with bevacizumab, capecitabin, and mitomycin C (BECAM) for patients with metastatic colorectal or gastric cancer refractory to 5fluorouracil, oxaliplatin, irinotecan, and cetuximab. ECCO abstract no 793

54.

Dorligschaw O, Kegel T, Jordan K, Harba A, Grothey A, Schmoll H-J (2003) ZD1839 (Iressa)-based treatment as last-line therapy in patients with advanced colorectal cancer (ACRC). Proc ASCO, annual meeting, abstract no 1494

55.

Hecht J, Mitchell E, Baranda J, Malik I, Richards D, Navale L, D’Avirro P, Amado R (2006) Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing low (1–9%) or negative (<1%) levels of epidermal growth factor receptor (EGFr). Proc ASCO, annual meeting, abstract no 3547

56.

Berlin J, Neubauer M, Swanson P, Harker G, Burris H, Hecht JR, Navale L (2006) Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing ≥10% epidermal growth factor receptor (EGFr). Proc ASCO, annual meeting, abstract no 3548

57.

Gebbia V, Del Prete S, Borsellino N, Ferraù F, Tralongo P, Verderame F, Leonardi V, Capasso E, Maiello E, Bordonaro R, Stinco S, Aqostara B, Barone C (2006) Efficacy and safety of cetuximab/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience. Clin Colorectal Cancer 5(6):422–428PubMedCrossRef

58.

Levi F, Karaboue A, Jasmin C, Innominto P, Machover D, Kunstlinger F, Castagne V, Adam R, Guettier C, Bouchahda M (2005) Cetuximab reversal of chemotherapy resistance in patients with extensively pretreated metastatic colorectal cancer treated at Paul-Brousse hospital. ECCO abstract no 710

59.

NCI 2007. www.cancer.gov. Health professional version

60.

Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomised GERCOR study. J Clin Oncol 22(2):229–237PubMedCrossRef

61.

Adjei AA (1999) A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer. Br J Clin Pharmacol 48(3):265–277PubMedCrossRef

62.

Goetz MP, Grothey A (2004) Developments in combination chemotherapy for colorectal cancer. Expert Rev Anticancer Ther 4(4):627–637PubMedCrossRef

63.

Grothey A, Sargent D, Goldberg RM, Schmoll H-J (2004) Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil–leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22(7):1209–1214PubMedCrossRef

64.

de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18(16):2938–2947PubMed

65.

Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S (2001) Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 19(18):3801–3807PubMed

66.

Cocconi G, Cunningham D, Van Cutsem E, Francois E, Gustavsson B, van Hazel G, Kerr D, Possinger K, Hietschold SM (1998) Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex colorectal cancer study group. J Clin Oncol 16(9):2943–2952PubMed

67.

Hejna M, Kornek GV, Raderer M, Depisch D, Brodowicz T, Fiebiger WC, Scheithauer W (1998) Reinduction therapy with the same cytostatic regimen in patients with advanced colorectal cancer. Br J Cancer 78(6):760–764PubMed

68.

www.Merck.de. 2006

69.

Giantonio BJ, Catalano PJ, Meropol NJ, O’Dwyer J, Mitchell P, Alberts SR, Schwartz MA, Benson AB, Eastern Cooperative Oncology Group Study E3200 (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25(12):1539–1544PubMedCrossRef

70.

Saltz LB, Lenz H, Kindler H, Hochster H, Wadler S, Hoff P, Kemeny N, Hollywood E, Gonen M, Chen H (2005) Interim report of randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. Proc ASCO, Gastrointestinal Cancers Symposium, abstract no 169b

71.

Hecht JR, Patnaik A, Malik I Venook A, Berlin J, Croghan G, Wiens BL, Visonneau S, Jerian S, Meropol NJ (2004) ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): an updated analysis. Proc ASCO, annual meeting, abstract no 3511

72.

Goldberg RM, Rothenberg ML, Van Cutsem E, Benson AB, Blanke CD, Diasio RB, Grothey A, Lenz H-J, Meropol NJ, Ramanathan RK, Becerra CHR, Wickham R, Armstrong D, Viele C (2007) The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist 12(1):38–50PubMedCrossRef

73.

Grothey A, Deschler B, Kroening H, Ridwelski K, Reichardt P, Kretzscmar A, Clemens M, Hirschmann W, Lorenz M, Asperger W, Buechele T, Schmoll H-J (2002) Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (MAYO) vs. weekly high-dose 24h 5-FU infusion/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proc ASCO, annual meeting, abstract no 512

74.

Cheeseman SL, Joel SP, Chester JD, Wilson G, Dent JT, Richards FJ, Seymour MT (2002) A “modified de Gramont” regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br J Cancer 87(4):393–399PubMedCrossRef

75.

Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan study group. N Engl J Med 343(13):905–914PubMedCrossRef

76.

Giacchetti S, Bjarnason G, Garufi C, Genet D, Iacobelli S, Tampellini M, Smaaland R, Focan C, Coudert B, Humblet Y, Canon JL, Adenis A, Lo Re G, Carvalho C, Schueller J, Anciaux N, Lentz MA, Baron B, Gorlia T, Levi F (2006) Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group. J Clin Oncol 24(22):3562–3569PubMedCrossRef

77.

Maindrault-Goebel F, de Gramont A, Louvet C, Andre T, Carola E, Gilles V, Lotz JP, Tournigand C, Mabro M, Molitor JL, Artru P, Izrael V, Krulik M (2000) Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). Ann Oncol 11(11):1477–1483PubMedCrossRef

78.

Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, Mineur L, Carola E, Etienne PL, Rivera F, Chirivella I, Perez-Staub N, Louvet C, Antré T, Tabah-Fisch I, de Gramont A (2006) OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-GO fashion advanced colorectal cancer–a GERCOR study. J Clin Oncol 24(3):394–400PubMedCrossRef

79.

Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, Debraud F, Figer A, Grossmann J, Sawada N, Schöffski P, Sobrero A, Van Cutsem E, Díaz-Rubio E (2004) XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 22(11):2084–2091PubMedCrossRef

Title: Third-line therapy for metastatic colorectal cancer
Authors: M. G. Gundgaard
J. B. Soerensen
E. Ehrnrooth
Publication date: 01-01-2008
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 1/2008
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-007-0573-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2008

A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer

Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring

Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas

Pharmacometrics and delivery of novel nanoformulated PEG-b-poly(ε-caprolactone) micelles of rapamycin

The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer

Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice

Keynote webinar | Spotlight on antibody–drug conjugates in cancer